Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Stegmeier

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2011
Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signalingAlix Scholer-Dahirel, Michael R Schlabach, Alice Loo, et al.
Cell|January 25, 2020
Quantitative Proteomics of the Cancer Cell Line EncyclopediaDavid P Nusinow, John Szpyt, Mahmoud Ghandi, et al.
Nature Medicine|April 8, 2015
Studying clonal dynamics in response to cancer therapy using high-complexity barcodingHyo-eun C Bhang, David A Ruddy, Viveksagar Krishnamurthy Radhakrishna, et al.
Cancer Discovery|June 5, 2016
CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic RegionsDiana M Munoz, Pamela J Cassiani, Li Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2014
Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancersGregory R Hoffman, Rami Rahal, Frank Buxton, et al.
Elife|February 2, 2017
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancerElsa B Krall, Belinda Wang, Diana M Munoz, et al.
Nature Medicine|December 24, 2013
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphomaRami Rahal, Mareike Frick, Rodrigo Romero, et al.
Cancer Research|October 15, 2024
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient TumorsLouise Cadzow, Jehrod Brenneman, Erica Tobin, et al.
The Journal of Clinical Investigation|December 15, 2023
Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screensMichael R Schlabach, Sharon Lin, Zachary R Collester, et al.
Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|September 28, 2011
Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signalingAlix Scholer-Dahirel, Michael R Schlabach, Alice Loo, et al.
Cell|January 25, 2020
Quantitative Proteomics of the Cancer Cell Line EncyclopediaDavid P Nusinow, John Szpyt, Mahmoud Ghandi, et al.
Nature Medicine|April 8, 2015
Studying clonal dynamics in response to cancer therapy using high-complexity barcodingHyo-eun C Bhang, David A Ruddy, Viveksagar Krishnamurthy Radhakrishna, et al.
Cancer Discovery|June 5, 2016
CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic RegionsDiana M Munoz, Pamela J Cassiani, Li Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2014
Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancersGregory R Hoffman, Rami Rahal, Frank Buxton, et al.
Elife|February 2, 2017
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancerElsa B Krall, Belinda Wang, Diana M Munoz, et al.
Nature Medicine|December 24, 2013
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphomaRami Rahal, Mareike Frick, Rodrigo Romero, et al.
Cancer Research|October 15, 2024
The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient TumorsLouise Cadzow, Jehrod Brenneman, Erica Tobin, et al.
The Journal of Clinical Investigation|December 15, 2023
Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screensMichael R Schlabach, Sharon Lin, Zachary R Collester, et al.
Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.
Pageof 4